Emerging drugs for ovarian cancer
Author:
Publisher
Informa Healthcare
Subject
Pharmacology (medical),Pharmacology
Link
http://www.tandfonline.com/doi/pdf/10.1517/14728214.10.2.413
Reference80 articles.
1. Contribution of BRCA1 and BRCA2 to Familial Ovarian Cancer: A Gynecologic Oncology Group Study
2. Mucinous Epithelial Ovarian Cancer: A Separate Entity Requiring Specific Treatment
3. Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
4. Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
5. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds
Cited by 35 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. AADAC promotes therapeutic activity of cisplatin and imatinib against ovarian cancer cells;HISTOL HISTOPATHOL;2022
2. NDRG2 gene expression pattern in ovarian cancer and its specific roles in inhibiting cancer cell proliferation and suppressing cancer cell apoptosis;Journal of Ovarian Research;2020-04-28
3. Theranostic Nanostructures for Ovarian Cancer;CRIT REV THER DRUG;2019
4. Curcumin Acts as a Chemosensitizer for Leiomyosarcoma Cells In Vitro But Fails to Mediate Antioxidant Enzyme Activity in Cisplatin-Induced Experimental Nephrotoxicity in Rats;Integrative Cancer Therapies;2019-01
5. Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities;Journal of Controlled Release;2018-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3